These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 11235926)

  • 1. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
    Clark WS; Street JS; Feldman PD; Breier A
    J Clin Psychiatry; 2001 Jan; 62(1):34-40. PubMed ID: 11235926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.
    Street JS; Clark WS; Gannon KS; Cummings JL; Bymaster FP; Tamura RN; Mitan SJ; Kadam DL; Sanger TM; Feldman PD; Tollefson GD; Breier A
    Arch Gen Psychiatry; 2000 Oct; 57(10):968-76. PubMed ID: 11015815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia.
    Street JS; Clark WS; Kadam DL; Mitan SJ; Juliar BE; Feldman PD; Breier A
    Int J Geriatr Psychiatry; 2001 Dec; 16 Suppl 1():S62-70. PubMed ID: 11748789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies.
    Cummings JL; Street J; Masterman D; Clark WS
    Dement Geriatr Cogn Disord; 2002; 13(2):67-73. PubMed ID: 11844887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis.
    Mintzer J; Faison W; Street JS; Sutton VK; Breier A
    Int J Geriatr Psychiatry; 2001 Dec; 16 Suppl 1():S71-7. PubMed ID: 11748790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.
    De Deyn PP; Carrasco MM; Deberdt W; Jeandel C; Hay DP; Feldman PD; Young CA; Lehman DL; Breier A
    Int J Geriatr Psychiatry; 2004 Feb; 19(2):115-26. PubMed ID: 14758577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
    Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
    Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms.
    Ballard C; Youakim JM; Coate B; Stankovic S
    J Prev Alzheimers Dis; 2019; 6(1):27-33. PubMed ID: 30569083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
    Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
    J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis.
    Ballard CG; Coate B; Abler V; Stankovic S; Foff E
    Int J Geriatr Psychiatry; 2020 Nov; 35(11):1402-1408. PubMed ID: 32729631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
    Sultzer DL; Davis SM; Tariot PN; Dagerman KS; Lebowitz BD; Lyketsos CG; Rosenheck RA; Hsiao JK; Lieberman JA; Schneider LS;
    Am J Psychiatry; 2008 Jul; 165(7):844-54. PubMed ID: 18519523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
    Wilcock GK; Ballard CG; Cooper JA; Loft H
    J Clin Psychiatry; 2008 Mar; 69(3):341-8. PubMed ID: 18294023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease.
    Kennedy JS; Zagar A; Bymaster F; Nomikos G; Trzepacz PT; Gilmore JA; Rotelli MD; Breier A; Tollefson G
    Int J Geriatr Psychiatry; 2001 Dec; 16 Suppl 1():S24-32. PubMed ID: 11748787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome.
    Breier A; Berg PH
    Biol Psychiatry; 1999 Aug; 46(3):361-4. PubMed ID: 10435201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
    Cummings JL; Koumaras B; Chen M; Mirski D;
    Am J Geriatr Pharmacother; 2005 Sep; 3(3):137-48. PubMed ID: 16257816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.
    Devanand DP; Marder K; Michaels KS; Sackeim HA; Bell K; Sullivan MA; Cooper TB; Pelton GH; Mayeux R
    Am J Psychiatry; 1998 Nov; 155(11):1512-20. PubMed ID: 9812111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
    Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P
    Arch Gen Psychiatry; 2002 May; 59(5):441-8. PubMed ID: 11982448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.